Retatrutide vs Tirzepatide vs Semaglutide: Triple vs Dual vs Single Agonist

How They Work

Semaglutide, tirzepatide, and retatrutide represent three generations of incretin-based weight loss medications. Each one activates more metabolic receptors than the last. That progressive receptor addition is the single most important concept for understanding why their clinical results escalate the way they do.

Semaglutide is a GLP-1 receptor agonist. It targets one receptor: GLP-1 (glucagon-like peptide-1). GLP-1 is a gut hormone released after eating. It reduces appetite by acting on receptors in the hypothalamus, slows gastric emptying so food stays in the stomach longer, and stimulates insulin release to regulate blood sugar. Your body produces GLP-1 naturally, but the natural version degrades within minutes. Semaglutide is an engineered analog that resists breakdown, maintaining active GLP-1 receptor stimulation for a full seven days from a single injection.

The appetite suppression from semaglutide is not simply "feeling less hungry." It acts on the brain's hunger regulation center and changes the underlying signal. Patients describe the constant mental noise around food -- cravings, preoccupation, the effort of willpower -- going quiet. One receptor. One pathway. One mechanism of action.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It activates two incretin receptors instead of one. GIP (glucose-dependent insulinotropic polypeptide) is actually the dominant incretin hormone in healthy humans -- your body releases more GIP than GLP-1 after a meal. GIP receptors exist in fat tissue, the pancreas, the brain, and bone. By engaging both pathways simultaneously, tirzepatide creates a broader metabolic effect than GLP-1 stimulation alone.

The GIP component does several things that matter. It appears to enhance insulin sensitivity independently of GLP-1, improve fat oxidation (the body's ability to burn stored fat for energy), and may contribute to better lean mass preservation during weight loss. GIP receptor signaling in the brain also appears to amplify the appetite-suppressing effects of GLP-1, making the dual agonist more potent than either pathway alone. Two receptors. Two pathways. Additive effect.

Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist. It does everything tirzepatide does, then adds activation of the glucagon receptor -- the third and newest piece of this puzzle. Glucagon is a hormone most people associate with raising blood sugar. That is one of its functions. But glucagon receptors also drive thermogenesis (heat production from burning calories), increase energy expenditure, accelerate lipid oxidation in the liver, and promote hepatic fat clearance. In simple terms: glucagon receptor activation tells the body to burn more energy, especially stored fat in and around the liver.

This is not a trivial addition. The glucagon component fundamentally changes the metabolic equation. Semaglutide and tirzepatide work primarily by reducing energy intake -- you eat less. Retatrutide does that and increases energy expenditure. It attacks the energy balance equation from both sides. Three receptors. Three pathways. Both reduced intake and increased output.

All three medications are administered as once-weekly subcutaneous injections. All three require gradual dose titration over weeks to months to manage gastrointestinal side effects. Semaglutide titrates from 0.25 mg up to 2.4 mg. Tirzepatide titrates from 2.5 mg up to 15 mg. Retatrutide titrated from 1 mg up to 12 mg in the Phase 2 trial. But despite these structural similarities in administration, their mechanisms produce meaningfully different outcomes in clinical trials -- and those differences map directly to the number of receptors each molecule activates.

What the Research Shows

The clinical evidence base for these three medications is at very different stages of maturity. Semaglutide has the deepest evidence, with multiple completed Phase 3 programs and post-market data across millions of patients. Tirzepatide has robust Phase 3 data and rapidly growing real-world evidence. Retatrutide has a single published Phase 2 trial. Comparing them requires acknowledging those evidence gaps honestly.

Semaglutide: The STEP Trial Program. The STEP (Semaglutide Treatment Effect in People with Obesity) trials form the foundation of semaglutide's evidence base. STEP 1, published in the New England Journal of Medicine in 2021 (PMID: 33567185), enrolled 1,961 adults with obesity or overweight with at least one weight-related comorbidity. Participants on semaglutide 2.4 mg lost an average of 14.9% of their body weight at 68 weeks, compared to 2.4% with placebo. One-third of participants lost more than 20% of their body weight.

Follow-up trials expanded the picture. STEP 2 showed 9.6% weight loss in patients with type 2 diabetes (patients with diabetes typically lose less weight on GLP-1 agonists). STEP 3 combined semaglutide with intensive behavioral therapy and achieved 16.0%. STEP 5 extended observation to 104 weeks, showing durable weight loss of approximately 15% as long as treatment continued. The consistent finding across the STEP program: semaglutide at 2.4 mg produces 15-17% average body weight loss in non-diabetic populations.

Tirzepatide: The SURMOUNT Trial Program. The SURMOUNT trials tested tirzepatide specifically for chronic weight management. SURMOUNT-1, published in the New England Journal of Medicine in 2022 (PMID: 35658024), enrolled 2,539 adults. At 72 weeks, participants lost an average of 15.0% (5 mg dose), 19.5% (10 mg dose), and 20.9% (15 mg dose) of their body weight. Using an estimand that accounted for treatment adherence, the highest dose group achieved 22.5% average weight loss. More than one-third of participants on the 15 mg dose lost more than 25% of their body weight.

SURMOUNT-2 studied tirzepatide in adults with obesity and type 2 diabetes (PMID: 37840095) and still produced 14.7% weight loss at the highest dose. SURMOUNT-3 and SURMOUNT-4 examined lifestyle therapy combinations and treatment withdrawal, respectively. The consistent SURMOUNT finding: tirzepatide at maximum doses produces 20-26% average weight loss, approximately 5-8 percentage points more than semaglutide.

Retatrutide: Phase 2 Data. The pivotal retatrutide Phase 2 trial, published in the New England Journal of Medicine in 2023 (PMID: 37385337), enrolled 338 adults with obesity. At 48 weeks, participants on the highest dose (12 mg) achieved an average weight loss of 24.2%. At the same dose, 26% of participants lost more than 30% of their body weight. Weight loss curves had not plateaued at 48 weeks, suggesting that longer treatment durations in Phase 3 trials could produce even greater reductions.

Two things make the retatrutide data particularly striking. First, the 24.2% weight loss at 48 weeks was achieved in a shorter timeframe than the STEP or SURMOUNT trials (which ran 68-72 weeks). Second, the trial showed significant reductions in liver fat content. At the 12 mg dose, mean liver fat decreased by approximately 81% from baseline, with the majority of participants achieving normal liver fat levels. This hepatic benefit is directly attributable to the glucagon receptor component and distinguishes retatrutide from both semaglutide and tirzepatide.

The generational pattern. Lining up the data across all three trial programs reveals a clear trajectory. Semaglutide: 15-17% weight loss. Tirzepatide: 20-26%. Retatrutide: 24-26% (and still climbing at 48 weeks). For a 250-pound person, that translates to roughly 40 pounds on semaglutide, 55 pounds on tirzepatide, and potentially 60-65 pounds on retatrutide. Each generation adds a receptor, and each receptor addition corresponds to meaningfully greater weight loss.

Cardiovascular outcomes: A critical evidence gap. Semaglutide has a major advantage that neither competitor can match today. The SELECT trial (PMID: 37952131), published in the New England Journal of Medicine in 2023, enrolled 17,604 adults with overweight or obesity and established cardiovascular disease. Semaglutide reduced major adverse cardiovascular events -- a composite of heart attack, stroke, and cardiovascular death -- by 20% over a mean follow-up of 39.8 months. This was not just a weight loss finding. It proved that semaglutide directly reduces the risk of cardiovascular events.

Tirzepatide's SURPASS-CVOT trial is underway but results are not expected for several years. Retatrutide has no cardiovascular outcomes trial even planned at this stage. For patients with established cardiovascular disease, this evidence gap matters. Semaglutide is the only one of these three medications with proven heart benefit.

Important caveats. No head-to-head trial has compared all three medications directly. Cross-trial comparisons (different populations, different endpoints, different timeframes) are inherently imperfect. Retatrutide data comes from a single Phase 2 trial with 338 participants -- orders of magnitude smaller than the STEP and SURMOUNT programs. Phase 3 results could confirm, narrow, or even reverse the preliminary findings. These numbers are population averages. Individual responses vary based on genetics, baseline metabolic health, diet, exercise, starting weight, and adherence.

Dosing and Titration: Side by Side

All three medications follow the same basic principle: start low, go slow. Titration exists to give your body time to adjust. Rushing it does not speed up weight loss. It just makes you nauseous.

Semaglutide titration schedule (Wegovy):

Weeks	Dose	Notes
1-4	0.25 mg	Starting dose. Minimal weight loss expected.
5-8	0.5 mg	Most patients begin noticing appetite changes.
9-12	1.0 mg	Significant appetite suppression for most.
13-16	1.7 mg	Approaching therapeutic range.
17+	2.4 mg	Full maintenance dose. This is where trial results were measured.

Total titration: 16 weeks to reach full dose. Most weight loss occurs after reaching 1.0 mg or higher.

Tirzepatide titration schedule (Zepbound):

Weeks	Dose	Notes
1-4	2.5 mg	Starting dose. GI adjustment period.
5-8	5.0 mg	First therapeutic dose level.
9-12	7.5 mg	Optional intermediate step.
13-16	10.0 mg	Strong efficacy for most patients.
17-20	12.5 mg	Optional intermediate step.
21+	15.0 mg	Maximum dose. Highest weight loss in trials.

Total titration: 20 weeks to reach maximum dose. Many patients see substantial results at 10 mg and do not need to go to 15 mg.

Retatrutide titration schedule (Phase 2 trial protocol):

Weeks	Dose	Notes
1-4	1.0 mg	Starting dose.
5-8	2.0 mg	First escalation.
9-12	4.0 mg	Moderate dose.
13-16	8.0 mg	Approaching maximum.
17+	12.0 mg	Highest dose tested in Phase 2.

Total titration: 16 weeks. Note: this was the Phase 2 protocol. Phase 3 trials may use a different schedule, and there is no FDA-approved label yet.

Key differences in dosing approach. Semaglutide uses small, incremental steps. Tirzepatide uses larger jumps with optional intermediate doses. Retatrutide (in Phase 2) used a faster escalation with larger dose doublings. The common thread: four-week intervals between increases. If you tolerate a dose well for four weeks, you move up. If side effects are significant, you stay at the current dose until they resolve.

Injection day consistency matters. All three are once-weekly. Pick the same day each week. It does not matter which day. What matters is consistency. If you miss a dose by a day or two, take it when you remember and resume your regular schedule. If you miss by more than two days, most guidelines recommend skipping that week and resuming on schedule. Your prescriber may have specific instructions.

Switching Between Medications

Switching between semaglutide and tirzepatide is increasingly common. Reasons include: inadequate weight loss response on one, insurance coverage changes, side effect intolerance, or a desire for greater efficacy. Switching to or from retatrutide is not a standard clinical scenario since it is not FDA-approved.

Semaglutide to tirzepatide. This is the most common switch direction. The standard protocol is to start tirzepatide at 2.5 mg regardless of what semaglutide dose you were on. There is no validated dose-conversion formula. Restarting at the lowest dose minimizes GI side effects during the transition and accounts for the fact that tirzepatide acts on a different receptor profile. Most clinicians recommend stopping semaglutide and starting tirzepatide the following week (on your normal injection day). No washout period is necessary.

Tirzepatide to semaglutide. Less common (since tirzepatide typically produces more weight loss), but it happens. Some patients switch due to insurance changes, cost, or personal preference. Same principle: start semaglutide at 0.25 mg and follow standard titration. Again, no washout needed.

What to expect when switching. The first 4-8 weeks after a switch can feel like starting over. GI side effects may return during retitration. Weight loss may temporarily stall or slow while your body adjusts to the new medication. This is normal and expected. By weeks 8-12 on the new medication, most patients are back on a weight loss trajectory.

When switching makes sense. Consider a switch if: you have been at maximum dose for 12+ weeks with less than expected results, your side effects remain problematic despite proper titration, or your access/insurance situation changes. Do not switch just because weight loss has slowed. Weight loss naturally decelerates as you lose more weight. A plateau at month 8 is different from poor response at month 3. Discuss timing with your prescriber.

Timeline to Results

One of the most common questions: "How fast will I lose weight?" Here is what the clinical data and real-world experience show for each medication.

First 4 weeks (all three). Do not expect much. The starting doses are subtherapeutic. They exist for GI adjustment, not weight loss. Some patients notice mild appetite changes. Others feel nothing. Weight loss during month one is typically 1-3% of body weight, mostly from reduced food intake as appetite shifts.

Weeks 4-12. This is where the medications start working. As doses escalate, appetite suppression increases noticeably. Most patients on semaglutide report a clear shift around the 1.0 mg dose (weeks 9-12). Tirzepatide patients often notice it at 5.0 mg (weeks 5-8). Weight loss accelerates to roughly 1-2% of body weight per month.

Weeks 12-24. Peak weight loss velocity for all three. This is the steepest part of the curve. Monthly weight loss of 2-4% of body weight is common once maintenance doses are reached. Food noise is typically at its lowest. Patients describe this as the "honeymoon period."

Weeks 24-48. Weight loss continues but decelerates. This is not a plateau. It is the expected mathematical pattern. As you lose weight, your caloric needs decrease, and the medication has less excess weight to act on. Monthly losses may slow to 0.5-1% of body weight. This phase can feel discouraging, but it is normal.

Beyond 48 weeks. Weight loss curves for semaglutide and tirzepatide generally flatten between months 12-15. The STEP 5 trial showed weight was maintained at approximately 15% loss through 104 weeks of continuous treatment. Tirzepatide's SURMOUNT-4 extension data showed similar maintenance. Retatrutide's 48-week data had not yet plateaued, suggesting its peak effect may extend further. But the pattern will eventually be the same: weight loss, followed by weight stability at a lower setpoint.

Individual variation is significant. These are averages. Some people lose 30%+ of their body weight. Others lose 5-8% and stall. Genetics, metabolic health, diet quality, exercise habits, sleep, stress, and medication adherence all influence outcomes. If your results do not match the averages, that does not mean the medication is not working. It means your body is responding on its own curve.

What Happens When You Stop

This is the question most people avoid. The answer is direct: if you stop any of these medications, you will regain a significant portion of the weight you lost. This is not a flaw in the medications. It is the biology of obesity.

The STEP 1 extension data. After the 68-week STEP 1 trial, participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. Patients who lost 15% regained roughly 10% over the following 52 weeks. The appetite suppression, reduced food noise, and metabolic changes reverse when the medication is removed.

The SURMOUNT-4 withdrawal data. SURMOUNT-4 specifically studied what happens when tirzepatide is discontinued. After 36 weeks of treatment, patients who switched to placebo regained approximately 14% of their body weight over the next 52 weeks, versus continued loss in those who stayed on the drug. The message was clear: stopping treatment reverses a large portion of the benefit.

Why this happens. Obesity involves changes in appetite-regulating hormones, metabolic rate, and brain signaling that persist even after weight loss. When you lose weight through any method (medication, surgery, diet), your body increases hunger hormones (ghrelin), decreases satiety hormones (leptin), and lowers metabolic rate in an attempt to return to its previous weight. GLP-1 medications suppress these compensatory mechanisms. Remove the medication, and the mechanisms reassert themselves.

What this means practically. These medications are designed for long-term, potentially lifelong use. They are treatments for a chronic condition, similar to blood pressure medication or statins. Stopping them "once you reach your goal weight" is like stopping blood pressure medication because your numbers improved. The numbers improved because of the medication.

Some patients do maintain weight off-medication. A minority of patients who combine medication with significant lifestyle changes (regular exercise, dietary habits, behavioral therapy) maintain some or most of their weight loss after stopping. But this is the exception, not the rule. If you are considering stopping, discuss a structured plan with your physician rather than simply discontinuing.

The Liver Fat Question

Retatrutide's liver fat reduction deserves separate attention because it represents a genuinely different clinical benefit from the other two.

Nonalcoholic fatty liver disease (NAFLD, now called MASLD) and its more severe form MASH (formerly NASH) affect an estimated 30% of the global population. MASH can progress to cirrhosis and liver failure. There are very few effective treatments. Weight loss helps, but the amount needed (typically 7-10% of body weight) is difficult for most patients to achieve and maintain.

In the retatrutide Phase 2 trial, mean liver fat content decreased by approximately 81% from baseline at the 12 mg dose. The majority of participants with elevated liver fat at baseline achieved normal liver fat levels by week 48. For context: semaglutide reduces liver fat by approximately 30-40% in studies, and tirzepatide by approximately 35-55%. Retatrutide's effect is roughly double.

This is attributed to the glucagon receptor component. Glucagon directly promotes hepatic fat oxidation (the liver burning its own fat stores) and inhibits de novo lipogenesis (the liver making new fat). This is a mechanism that semaglutide and tirzepatide simply do not have.

If you have been diagnosed with fatty liver disease, MASLD, or MASH, this distinction matters. It does not make retatrutide "better" in general. But for this specific condition, the triple agonist mechanism has a theoretical and early empirical advantage that neither single nor dual agonists match.

Side Effects and Tolerability

The side effect profiles of all three medications overlap substantially. Gastrointestinal symptoms dominate, particularly during dose titration. The pattern is similar across all three: most side effects are mild to moderate, peak during dose escalation, and improve with continued use.

Nausea is the primary side effect across all three. In STEP 1, 44.2% of semaglutide participants reported nausea at some point during the trial, though the majority experienced it as mild to moderate and transient. In SURMOUNT-1, nausea rates were 24.6% to 33.3% across tirzepatide dose groups. In the retatrutide Phase 2 trial, nausea affected approximately 25-45% of participants depending on dose. Vomiting followed a parallel distribution: 24.8% for semaglutide 2.4 mg, 8.3-12.2% for tirzepatide, and roughly 10-18% for retatrutide.

There is an interesting pattern here. Tirzepatide appears to cause fewer GI side effects than semaglutide despite producing greater weight loss. Researchers attribute this to the GIP receptor component, which appears to partially buffer the gastrointestinal disturbance that pure GLP-1 agonism causes. Retatrutide's GI profile in Phase 2 was broadly similar to tirzepatide's, though the glucagon receptor component introduces its own set of tolerability considerations -- most notably, transient increases in heart rate observed at higher doses.

Titration pace remains critical for all three. The majority of GI side effects occur during dose escalation, not at stable maintenance doses. All three medications use slow titration schedules, typically with four-week steps between dose increases. Patients who rush titration or skip dose levels consistently experience worse nausea and vomiting. This is as true for retatrutide as it is for the approved agents.

Heart rate effects. Modest increases in resting heart rate (2-4 beats per minute on average) have been observed with semaglutide and tirzepatide. The retatrutide Phase 2 trial showed heart rate increases of approximately 2-6 bpm at higher doses. The glucagon receptor is the likely contributor to the slightly larger heart rate effect, since glucagon has known chronotropic (heart-rate-increasing) properties. Whether this translates to any clinically meaningful cardiovascular risk is unknown and will need to be evaluated in larger, longer trials.

Serious adverse events. In the major semaglutide and tirzepatide trials, rates of acute pancreatitis were low (less than 0.3%) and not statistically different from placebo. Gallbladder events occurred at slightly elevated rates, consistent with rapid weight loss from any cause. Both carry an FDA boxed warning about the risk of medullary thyroid carcinoma based on rodent studies, though this has not been observed in humans. Retatrutide Phase 2 data did not reveal new safety signals, but the study was too small and too short to detect rare events. Phase 3 trials and post-market surveillance will be essential.

Muscle loss remains a shared concern. Rapid weight loss from any intervention results in some loss of lean body mass alongside fat mass. Semaglutide data showed approximately 39% of total weight lost was lean mass. Tirzepatide showed a somewhat more favorable ratio, with a higher proportion of fat mass lost relative to lean mass -- possibly due to GIP receptor activation in muscle tissue. Retatrutide body composition data from Phase 2 is limited, but the glucagon receptor's role in promoting fat oxidation over protein catabolism could theoretically further improve the fat-to-lean loss ratio. This remains speculative until more data is available.

All major clinical guidelines recommend resistance training (at least two sessions per week) and adequate protein intake (1.0-1.2 grams per kilogram of body weight per day minimum) alongside any of these medications. The medication handles appetite. The patient has to handle muscle preservation.

Cost, Access, and Practical Considerations

Clinical data only matters if you can actually access the medication. For these three compounds, the access landscape is radically different.

Semaglutide and tirzepatide are FDA-approved and commercially available. Wegovy (semaglutide 2.4 mg for obesity) lists at roughly $1,350 per month. Zepbound (tirzepatide for obesity) lists at approximately $1,060 per month. Without insurance or manufacturer savings programs, both are out of reach for most patients. Insurance coverage currently favors semaglutide due to its longer time on market -- Wegovy was approved in June 2021, Zepbound in November 2023. That two-year head start gave semaglutide time to establish broader formulary placement. Tirzepatide coverage is expanding but has not caught up.

Retatrutide is not commercially available. It is in Phase 3 clinical trials as of early 2026. If those trials succeed, FDA approval could come as early as 2027 or 2028. Until then, retatrutide is only accessible through clinical trial enrollment or through unregulated research peptide suppliers. Research peptide vendors are not pharmacies and are not regulated for human use. There is no quality assurance, no standardized dosing, and no medical oversight. This is an important distinction from compounded semaglutide or tirzepatide, which at least involve licensed pharmacies and prescriptions.

Compounding pharmacies. When semaglutide and tirzepatide were placed on the FDA Drug Shortage List, compounding pharmacies gained the legal ability to produce copies at significantly lower prices -- typically $150 to $500 per month. This expanded access for millions of patients who could not afford brand-name pricing. However, the FDA has been moving to resolve shortage designations as branded supply stabilizes, which could restrict compounded access. Litigation between compounding pharmacies and manufacturers is ongoing. No equivalent compounding pathway exists for retatrutide, since it has never been FDA-approved and therefore has no established shortage designation.

Medicare does not cover any of them. Medicare Part D does not currently cover anti-obesity medications. Legislative efforts to change this are underway but have not succeeded as of early 2026. For Medicare patients, all three medications (to the extent they are available) would require full out-of-pocket payment.

The timeline matters. This comparison spans three very different stages of the pharmaceutical lifecycle. Semaglutide has been prescribed to millions of patients over several years. Its supply chain, insurance infrastructure, and clinical protocols are mature. Tirzepatide is earlier in its commercial lifecycle but available and rapidly scaling. Retatrutide is years away from reaching a pharmacy shelf. Patients making treatment decisions today are choosing between semaglutide and tirzepatide. Retatrutide is relevant as a future option, not a current one.

Switching between available options. Patients who respond poorly to semaglutide or tirzepatide can switch to the other under medical supervision without a washout period. Most clinicians restart at the lowest dose and follow standard titration regardless of the prior medication. Switching to retatrutide is not an option outside of clinical trials.

The Bottom Line

These three medications tell the story of a field evolving in real time. Each generation adds a receptor, expands the metabolic reach, and pushes weight loss outcomes further than the last. Single agonist to dual agonist to triple agonist. 15% to 22% to 24% and climbing. It is a clear trajectory, and the science behind it is sound.

But more receptors does not automatically mean "better" for every patient. Each step forward in potency comes with a step backward in certainty.

Semaglutide has the deepest evidence base. Millions of patients. Years of post-market surveillance. A completed cardiovascular outcomes trial proving it reduces heart attacks and strokes by 20%. For patients with established cardiovascular disease, that SELECT trial data is not a footnote -- it may be the single most important data point in this entire comparison. Semaglutide also has the broadest insurance coverage and the most mature supply chain. It is the known quantity.

Tirzepatide has the strongest weight loss data among currently available medications. The dual GLP-1/GIP mechanism produces 5-8 percentage points more weight loss than semaglutide, with what appears to be a comparable or even more favorable side effect profile. Its evidence base is robust and growing. The main gap is the absence of a completed cardiovascular outcomes trial. For patients whose primary goal is maximum weight loss and who can access the medication, tirzepatide has the edge on efficacy.

Retatrutide has the most compelling early data and the most unknowns. The Phase 2 trial showed weight loss rivaling or exceeding tirzepatide at a shorter timeframe, plus dramatic liver fat reduction that neither competitor matches. The glucagon receptor component is genuinely novel -- it changes the mechanism from "eat less" to "eat less and burn more." But Phase 2 data from 338 patients cannot be treated with the same confidence as Phase 3 data from thousands. Retatrutide is a promising candidate, not a proven therapy. It is not FDA-approved, not commercially available, and years away from reaching most patients.

The generational framing is useful but should not be mistaken for a simple hierarchy. "Newer" does not mean "better for you right now." The right choice depends on what is available, what is affordable, what is covered, and what your physician recommends based on your individual health profile. For most people making a decision today, the choice is between semaglutide and tirzepatide. Retatrutide is the one to watch -- but watching is different from choosing.

None of these medications is a standalone solution. All three work best when combined with dietary changes, regular physical activity including resistance training, adequate protein intake, and ongoing medical supervision. All three require continued treatment to maintain results -- stopping any of them leads to significant weight regain. And all three are tools, not cures. The trajectory from single to dual to triple agonist is remarkable. But the fundamentals of chronic weight management have not changed.